Donald McDonnell: Successful Drug Discovery Through Collaboration and Strong Fundamental Research
Donald McDonnell, Professor in the Department of Pharmacology and Cancer Biology at Duke University School of Medicine, shared on LinkedIn about a recent paper by Surendra Nayak et al. published on Clinical Cancer Research:
“This new publication describes a fantastic collaboration between our colleagues at BMS and outstanding scientists in my group. This discovery project was successful as it leveraged very sound fundamental research from both groups that informed the path to the drug.”
Title: Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancer
Authors: Surendra Nayak, John D. Norris, Massimo Ammirante, Emily Rychak, Suzanne E. Wardell, Debbie Liao, Brandon Toyama, Raju Kandimalla, Andy Christoforou, Toshiya Tsuji, Ken Liu, Minerva Tran, Joseph Meiring, Samantha Reiss, Joseph R. Piccotti, Joshua M. Baughman, Celia Fontanillo, Marwa Khater, Deborah S. Mortensen, Brian Cathers, Neil Bence, Daniel W. Pierce, Veronique Plantevin-Krenitsky, Dana Rathkopf, Joshua D. Hansen, Lawrence G. Hamann, Rama Krishna Narla, Vivek K. Arora, Donald P. McDonnell, Mark Rolfe, Shuichan Xu
More posts featuring Donald McDonnell.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023